Advertisement

Pediatric Cardiology

, Volume 36, Issue 1, pp 165–170 | Cite as

The Value of Acetylcholine Receptor Antibody in Children with Postural Tachycardia Syndrome

  • Jiawei Li
  • Qingyou Zhang
  • Ying Liao
  • Chunyu Zhang
  • Hongjun Hao
  • Junbao DuEmail author
Original Article

Abstract

Postural tachycardia syndrome (POTS) is characterized by symptoms of orthostatic intolerance. Antibodies of acetylcholine receptor (AChR-ab) affect acetylcholine transmission between the ganglia and result in imbalance of the autonomic nervous system in POTS. This study was designed to analyze the clinical characteristics of POTS patients with AChR-ab positive and explore the value of AChR-ab in children with POTS. In 82 children with POTS, twenty patients (24.39 %) were found as AChR-ab positive. Their clinical characteristics and hemodynamic responses to orthostatic changes were compared with the remaining 60 patients with negative AChR-ab. Symptoms of POTS children with AChR-ab positive were significantly severe than those of AChR-ab negative patients (p = 0.001). Preceding infection was predominant in patients with AChR-ab positive compared with that of patients with AChR-ab negative (p < 0.001). Syncope and fatigue were more common in the AChR-ab positive patients (p < 0.05). The change of upright heart rate was increased significantly in AChR-ab positive patients compared with AChR-ab negative cases (p = 0.013). Multiple logistic regression analysis revealed that preceding infection (OR 22.356, 95 % CI 2.151–34.920), syncope (OR 11.570, 95 % CI 2.098–63.810), and fatigue (OR 11.145, 95 % CI 1.658–74.911) were independent risk factors for POTS with AChR-ab positive. In conclusion, POTS with positive AChR-ab was a heterogeneous disorder. Preceding infection, syncope and fatigue were their main clinical characteristics.

Keywords

Acetylcholine receptor antibody Children Clinical characteristics Orthostatic intolerance Postural tachycardia syndrome 

Notes

Acknowledgments

This work was supported by grants from the Beijing Committee of Science and Technology, China (Z121107001012051) and the National Twelfth 5-Year Plan for Science and Technology Support (2012BAI03B03).

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Chinese Pediatric Cardiology Society, Editorial Board of Chinese Journal of Pediatrics (2009) Guideline of diagnosis of syncope in children. Zhonghua Er Ke Za Zhi 47:99–100Google Scholar
  2. 2.
    Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I et al (2009) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72CrossRefGoogle Scholar
  3. 3.
    Gibbons CH, Freeman R (2009) Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. Auton Neurosci 146:8–12PubMedCrossRefGoogle Scholar
  4. 4.
    Grubb BP, Kanjwal Y, Kosinski DJ (2006) The postural tachycardia syndrome: a concise guide to diagnosis and management. J Cardiovasc Electrophysiol 17:108–112PubMedGoogle Scholar
  5. 5.
    Ishitobi M, Haginoya K, Kitamura T, Munakata M, Yokoyama H, Iinuma K (2004) Acute dysautonomia: Complete recovery after two courses of IVIG. Brain Dev 26:542–544PubMedCrossRefGoogle Scholar
  6. 6.
    Jarjour IT (2013) Postural tachycardia syndrome in children and adolescents. Semin Pediatr Neurol 20:18–26PubMedCrossRefGoogle Scholar
  7. 7.
    Johnson JN, Mack KJ, Kuntz NL, Brands CK, Porter CJ, Fischer PR (2010) Postural orthostatic tachycardia syndrome: a clinical review. Pediatr Neurol 42:77–85PubMedCrossRefGoogle Scholar
  8. 8.
    Kanjwal Y, Kosinski D, Grubb BP (2003) The postural orthostatic tachycardia syndrome definitions, diagnosis, and management. Pacing Clin Electrophysiol 26:1747–1757PubMedCrossRefGoogle Scholar
  9. 9.
    Kanjwal K, Karabin B, Sheikh M, Elmer L, Kanjwal Y, Saeed B et al (2011) Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol 34:750–755PubMedCrossRefGoogle Scholar
  10. 10.
    Low PA, Sandroni P, Joyner M, Shen WK (2009) Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol 20:352–358PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Oldstone MB (2005) Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr Top Microbiol Immunol 296:1–17PubMedGoogle Scholar
  12. 12.
    Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D (2005) Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 111:2734–2740PubMedCrossRefGoogle Scholar
  13. 13.
    Singer W, Sletten DM, Opfer-Gehrking TL, Brands CK, Fischer PR, Low PA (2012) Postural tachycardia in children and adolescents: what is abnormal? J Pediatr 160:222–226PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vernino S et al (2007) Postural orthostatic tachycardia syndrome: the mayo clinic experience. Mayo Clin Proc 82:308–313PubMedCrossRefGoogle Scholar
  15. 15.
    Tüzün E, Christadoss P (2013) Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev 12:904–911PubMedCrossRefGoogle Scholar
  16. 16.
    Vernino S, Lindstrom J, Hopkins S, Wang Z, Low PA, Muscle Study Group (2008) Characterization of ganglionic acetylcholine receptor autoantibodies. J Neuroimmunol 197:63–69PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Vernino S, Hopkins S, Wang Z (2009) Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 146:3–7PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Wang Z, Low PA, Jordan J, Freeman R, Gibbons CH, Schroeder C et al (2007) Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current. Neurology 68:1917–1921PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Wang XL, Ling TY, Charlesworth MC, Figueroa JJ, Low P, Shen WK et al (2013) Autoimmunoreactive IgGs against cardiac lipid raft-associated proteins in patients with postural orthostatic tachycardia syndrome. Transl Res 162:34–44PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Winker R, Barth A, Dorner W, Mayr O, Pilger A, Ivancsits S et al (2003) Diagnostic management of orthostatic intolerance in the workplace. Int Arch Occup Environ Health 76:143–150PubMedGoogle Scholar
  21. 21.
    Zhang F, Li X, Ochs T, Chen L, Liao Y, Tang C et al (2012) Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. J Am Coll Cardiol 60:315–320PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang Q, Liao Y, Tang C, Du J, Jin H (2012) Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome. J Pediatr 161:281–284PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Jiawei Li
    • 1
  • Qingyou Zhang
    • 1
  • Ying Liao
    • 1
  • Chunyu Zhang
    • 1
  • Hongjun Hao
    • 2
  • Junbao Du
    • 1
    Email author
  1. 1.Department of PediatricsPeking University First HospitalBeijingChina
  2. 2.Department of NeurologyPeking University First HospitalBeijingChina

Personalised recommendations